SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~~ Record Number of Patients and Pl…

FENC

Related stories